While recent literature [24], [27] indicates Dub3 as an eligible therapeutic target for cancers expressing Cdc25a, our results imply that its inhibition may be ineffective in tumor initiating cells, which actually don't rely on Dub3 function. Here, USP17L2 is linked to neoplasm.